Order:
  1.  73
    Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework.Niklaus H. Evitt, Shamik Mascharak & Russ B. Altman - 2015 - American Journal of Bioethics 15 (12):25-29.
    CRISPR germline editing therapies hold unprecedented potential to eradicate hereditary disorders. However, the prospect of altering the human germline has sparked a debate over the safety, efficacy, and morality of CGETs, triggering a funding moratorium by the NIH. There is an urgent need for practical paths for the evaluation of these capabilities. We propose a model regulatory framework for CGET research, clinical development, and distribution. Our model takes advantage of existing legal and regulatory institutions but adds elevated scrutiny at each (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   14 citations  
  2.  54
    Ontological Issues in Pharmacogenomics.Russ B. Altman - 2007 - The Monist 90 (4):523-533.
    No categories
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  3.  30
    Response to Open Peer Commentaries on “Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework”.Niklaus H. Evitt, Shamik Mascharak & Russ B. Altman - 2016 - American Journal of Bioethics 16 (10):1-2.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark